Sinusitis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 106 pages | ID: S0AE668B1D71EN
VPAResearch

Abstracts

2020 Sinusitis PIPELINE HIGHLIGHTS
Sinusitis is one of the widely researched conditions during 2020 with 20 companies actively focusing on realizing pipeline’s potential. Development of Sinusitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Sinusitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Sinusitis.

Good progress is anticipated during 2020 and 2021 with Sinusitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Sinusitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Sinusitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Sinusitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Sinusitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Sinusitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Sinusitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Sinusitis DRUG PROFILES
Sinusitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Sinusitis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Sinusitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Sinusitis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 20 Sinusitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Sinusitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- AnaptysBio Inc, Argenx SE, Armata Pharmaceuticals Inc, Blue Water Vaccines Inc, Fogangren Bio-Pharma Limited, GeneOne Life Science Inc, GlycoMira Therapeutics Inc, Gossamer Bio Inc, IVIEW Therapeutics Inc, Knopp Biosciences LLC, Kyowa Hakko Kirin Co Ltd, Lyra Therapeutics, Merck & Co Inc, Nota Laboratories LLC, OptiNose US Inc, Pfizer Inc, Precigen Inc, ProclaRx LLC, RAPT Therapeutics Inc, Sanotize

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Sinusitis
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO SINUSITIS

1.1 Sinusitis- Disease overview
1.2 Sinusitis- Market Size
1.3 Sinusitis- Companies Involved

2. SINUSITIS PIPELINE SNAPSHOT- 2020

2.1 Sinusitis Pipeline by Phase
2.2 Sinusitis Pipeline by Mechanism of Action
2.3 Sinusitis Pipeline by Route of Administration
2.4 Sinusitis Pipeline- New Molecular Entities
2.5 Sinusitis Pipeline- Orphan Drug Designation/ Special Designation

3. SINUSITIS DRUG PROFILES

3.1 Current Status
3.2 Sinusitis Drug Snapshot
3.3 Sinusitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 AnaptysBio Inc Sinusitis Pipeline Insights and Clinical Trials
4.2 Argenx SE Sinusitis Pipeline Insights and Clinical Trials
4.3 Armata Pharmaceuticals Inc Sinusitis Pipeline Insights and Clinical Trials
4.4 Blue Water Vaccines Inc Sinusitis Pipeline Insights and Clinical Trials
4.5 Fogangren Bio-Pharma Limited Sinusitis Pipeline Insights and Clinical Trials
4.6 GeneOne Life Science Inc Sinusitis Pipeline Insights and Clinical Trials
4.7 GlycoMira Therapeutics Inc Sinusitis Pipeline Insights and Clinical Trials
4.8 Gossamer Bio Inc Sinusitis Pipeline Insights and Clinical Trials
4.9 IVIEW Therapeutics Inc Sinusitis Pipeline Insights and Clinical Trials
4.10 Knopp Biosciences LLC Sinusitis Pipeline Insights and Clinical Trials
4.11 Kyowa Hakko Kirin Co Ltd Sinusitis Pipeline Insights and Clinical Trials
4.12 Lyra Therapeutics Sinusitis Pipeline Insights and Clinical Trials
4.13 Merck & Co Inc Sinusitis Pipeline Insights and Clinical Trials
4.14 Nota Laboratories LLC Sinusitis Pipeline Insights and Clinical Trials
4.15 OptiNose US Inc Sinusitis Pipeline Insights and Clinical Trials
4.16 Pfizer Inc Sinusitis Pipeline Insights and Clinical Trials
4.17 Precigen Inc Sinusitis Pipeline Insights and Clinical Trials
4.18 ProclaRx LLC Sinusitis Pipeline Insights and Clinical Trials
4.19 RAPT Therapeutics Inc Sinusitis Pipeline Insights and Clinical Trials
4.20 Sanotize Sinusitis Pipeline Insights and Clinical Trials

5. SINUSITIS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information